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Abstract
Background: Neurofibromatosis 1 and 2, although involving two different tumour suppressor genes (neurofibromin and
merlin, respectively), are both cancer predisposition syndromes that disproportionately affect cells of neural crest origin.
New therapeutic approaches for both NF1 and NF2 are badly needed. In promising previous work we demonstrated that
two non-steroidal analogues of 2-methoxy-oestradiol (2ME2), STX3451(2-(3-bromo-4,5-dimethoxybenzyl)-7-methoxy-6-
sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline), and STX2895 (7-Ethyl-6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-
tetrahydroisoquinoline) reduced tumour cell growth and induced apoptosis in malignant and benign human
Neurofibromatosis 1 (NF1) tumour cells. In earlier NF1 mechanism of action studies we found that in addition to their
effects on non-classical hormone-sensitive pathways, STX agents acted on the actin- and myosin-cytoskeleton, as well as
PI3Kinase and MTOR signaling pathways. Tumour growth in NF2 cells is affected by different inhibitors from those
affecting NF1 growth pathways: specifically, NF2 cells are affected by merlin-downstream pathway inhibitors. Because
Merlin, the affected tumour suppressor gene in NF2, is also known to be involved in stabilizing membrane-cytoskeletal
complexes, as well as in cell proliferation, and apoptosis, we looked for potentially common mechanisms of action in the
agents’ effects on NF1 and NF2. We set out to determine whether STX agents could therefore also provide a prospective
avenue for treatment of NF2.
Methods: STX3451 and STX2895 were tested in dose-dependent studies for their effects on growth parameters of
malignant and benign NF2 human tumour cell lines in vitro. The mechanisms of action of STX3451 and STX2895 were
also analysed.
Results: Although neither of the agents tested affected cell growth or apoptosis in the NF2 tumour cell lines tested
through the same mechanisms by which they affect these parameters in NF1 tumour cell lines, both agents disrupted
actin- and myosin-based cytoskeletal structures in NF2 cell lines, with subsequent effects on growth and cell death.
Conclusions: Both STX3451 and STX2895 provide new approaches for inducing cell death and lowering tumour burden
in NF2 as well as in NF1, which both have limited treatment options.
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Background
Both Neurofibromatosis 1 and 2 (NF1 and NF2) are dis-
orders characterized by the formation of tumours of the
peripheral and central nervous system [1], primarily af-
fecting cells of neural crest origin [2]. Although other
organ systems and cell types are affected in both NF1
and NF2, the cell of origin in most malignancies is the
Schwann cell [1]. Both NF disorders arise through auto-
somal dominant inheritance with loss-of-function muta-
tions in the tumour suppressing functions of the
respective tumour suppressor genes: Neurofibromin
(NF1) and Merlin (NF2) [3, 4].
Neurofibromatosis type II (NF2) is associated with
loss-of-function mutations in the NF2 gene that encodes
the multi-functional protein, Merlin (Moesin-Ezrin-
Radixin-like protein) [5], also known as Schwannomin.
Merlin is currently an out-group member of the ERM
(Ezrin-Radixin-Moesin) protein family because it is the
only one in the family to function as a tumour suppres-
sor. Strong evidence suggests that Merlin regulates the
assembly of apico-lateral junctional complex [6]. Merlin
is also involved in stabilizing membrane-cytoskeletal
complexes [7], in cell proliferation [8–10], and in apop-
tosis [10]. Conditional knockouts of Merlin result in the
formation of meningiomas [11]. Conditional deletion of
Merlin also contributes to hyperplasia of Schwann cells
and of neural-crest derived odontoblasts, osteoblasts,
and renal tubular cells. It also results in metastases of
osteoscarcoma and fibrosarcoma [12]. Loss of Merlin ac-
tivates several mitogenic pathways including Rac1/Pak
[13, 14], Ras/Raf, PI3K/AKT, mTORC1 and Wnt/β-ca-
tenin pathways [15, 16]. Merlin also mediates the Hippo
pathway and inhibits proliferation, acting in the nucleus
to bind E3 ubiquitin ligase CRL4DCAF1 [17].
NF2 affects one in 25,000–30,000 live births world-
wide. A hallmark of the disease is the formation of bilat-
eral vestibular Schwannomas, as well as the formation of
multiple meningiomas, extramedullary spinal tumours,
and ependymomas [18]. Uncontrolled growth of these
tumours can also lead to cataracts, hearing loss, balance
issues and paralysis [5, 6, 19]. Although malignant trans-
formations of NF2 tumours are rare, better therapeutics
are needed, because numerous tumours can lead to early
morbidity and early mortality (age 36) [5].
Current treatment options for NF2 tumours include
surgical resection of either part of or the complete
tumour, which is difficult to perform without damaging
nerves. Stereotactic radiosurgery is also an option, how-
ever the risk of malignant transformation rises several
years post-surgery [20, 21]. Alternate treatment options
for NF2 tumours include inhibitors of the epidermal
growth factor receptor (EGFR) [22], inhibitors of the
vascular endothelial growth factor (VEG-F) [23–25], in-
hibitors of mTORC1 [26], an inhibitor of platelet-
derived growth factor (PDGF) [27], and an inhibitor of
histone deacetylase (HDAC) [28]. However, such treat-
ments have resulted in mixed and sometimes limited suc-
cess in human trials [29]. Current phase II clinical trials
explore better treatment options through inhibition of the
mTORC1, PDGF-R, VEGF and anti-angiogenic pathways
(NCT01419639; NCT00561665; NCT00589784;
NCT02104323). To date, no phase III clinical trials for the
treatment of NF2-related disorders have been initiated.
Previous studies from our laboratories [30] demon-
strated that sulfamate ester derivatives of a class of non-
steroidal tetrahydroisoquinoline (THIQ)-derived agents,
derived by SAR translation from the naturally occurring
anticancer metabolite of 17-β estradiol, known as 2-
methoxyoestradiol (2ME2) [31, 32] are highly effective at
reducing cell viability in hormone-responsive NF1 cell
lines. These derivatives, known as STX3451 and
STX2895, are capable of inducing apoptosis in cell lines
derived from two malignant peripheral nerve sheath tu-
mours (MPNST) at very low concentration [30].
The two non-steroidal 2ME2 analogues, STX3451 (2-
(3-bromo-4,5-dimethoxybenzyl)-7-methoxy-6-sulfamoy-
loxy-1,2,3,4-tetrahydroisoquinoline) and STX2895 (7-
Ethyl-6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-
tetrahydroisoquinoline) (Fig. 1) were synthesized as pre-
viously described for treatment of a variety of hormone-
responsive cancers, including breast cancer and prostate
cancer [31–35]. STX3451 displays high anti-proliferative
activity across the NCI 60 cell line panel (average GI50
40 nM) [31]. STX2895 also has a high anti-proliferative
activity with GI50 of 40 and 52 nM on DU-145 human
prostate and MDA MB-231 breast cancer cell lines, re-
spectively [32]. The ability of STX3451and STX2895 to
disrupt normal microtubule dynamics through competi-
tive binding to the colchicine site, in a cell-free system,
appears to make a significant contribution to their anti-
proliferative effects [31, 32]. Sulfamoylated derivatives of
2ME2, particularly its bis-sulfamate 2ME2BisMATE,
have been shown to be more effective, more bioavailable,
resistant to catabolism in the gut and liver than 2ME2 it-
self [36], and also interact with carbonic anhydrase IX, a
hypoxic tumour target [37]. Although the bioavailability
of STX3451 and STX2895 has not been examined in an
animal model, the in-vitro effects of these molecules on
NF1 cell lines derived from both benign and malig-
nant human tumours are particularly promising [30].
These agents are multi-faceted with multiple modes
of action, including those that are hormone-
independent ([30]). Recently, some of us also demon-
strated that THIQ derivatives, including STX2895 and
STX3451 exert anti-proliferative and antimitotic ef-
fects, induce apoptosis and involve autophagic pro-
cesses in MDA-MB-231 metastatic breast and A549
epithelial lung carcinoma cell lines [38].
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Here, we show that NF2 status plays a role in the ef-
fectiveness of these non-steroidal 2ME2 derivatives on
cell viability in vitro. STX2895 and STX3451 treatment
on NF2 null (−/−) cell lines induces nuclear fragmenta-
tion, microtubular disruption, inhibition of cellular mi-
gration/wound healing, and can induce apoptosis in
both benign and malignant NF2 tumour-derived cells.
Methods
Cell culture
NF2-null malignant meningioma KT21-MG1-Luc5D
cells (KT21 cells, derived from a human malignant men-
ingioma cell line KT21-MG1 [39]) and the luciferase-
expressing NF2-deficient benign meningioma cell line,
Ben-Men-1-LucB (Ben-Men-1 cells, derived from a hu-
man benign meningioma cell line Ben-Men-1 [40]), have
been described previously [41]. CH157MN cells (a hu-
man malignant meningioma NF2−/− cell line from a 41-
year-old woman [42]) were generously provided by Dr.
Yancey Gillespie at the University of Alabama Birming-
ham. HEI-193 cells (a benign vestibular Schwannoma
cell line from a 56-year-old Neurofibromatosis type 2
(NF2) patient [43]) were kindly provided by Dr. Xandra
Breakefield, Massachusetts General Hospital. The
IOMM-Lee (a malignant Meningioma NF2+/+ cell line
derived from the brain of 61-year-old man [44]) was ob-
tained from Dr. Randy Jensen at the University of Utah.
BJ (ATCC® CRL-2522™, human foreskin fibroblast) cells
were a gift from Dr. Sem Hin Phan, University of Mich-
igan. Most cell lines were cultured in high-glucose Dul-
becco’s Modified Eagle Medium (DMEM) (Gibco),
supplemented with 10% fetal bovine serum (FBS)
(Atlanta Biologicals, Flowery Branch, GA), 2 mM L-glu-
tamine and 100 U/ml penicillin/streptomycin (Gibco), at
37 °C in a humidified 5% CO2 incubator [41]. HEI-193
cells were maintained in DMEM/10% FBS with forskolin
(Cayman Chemical, Ann Arbor, MI), recombinant glial
growth factor 2 (R&D Systems, Minneapolis, MN), and
geneticin (Gibco). CH157MN cells were grown in
MEM/F12 medium with 7% FBS.
Compounds
STX3451 and STX2895 were synthesized according to
previously published protocols [31, 45]. Pak inhibitors,
Frax1036 and PF3758309 were used as control to be
compared with the effects of STX3451 and STX2895 on
NF2-deficient cells. Frax1036 was purchased from
Afraxis Inc., San Diego, CA [39]. PF3758309 was synthe-
sized according to published protocols [46].
Cell viability assays
Cells were plated in 96-well Primaria™ plates (BD Fal-
con,1 × 104/well) determined by a hemocytometer.
STX3451 or STX2895 at concentrations of 100 nM, 300
nM, 600 nM, and 1000 nM was dissolved in vehicle
(DMSO; Sigma-Aldrich, St Louis, MO, USA) and were
added to the wells 2 hours after plating the cells. The
final concentration of DMSO was 1%. PF3758309 (PF)
and Frax1036 concentrations ranged from 0.03 μM to
20 μM and from 2.5 μM to 25 μM, respectively. The final
concentration of DMSO was 2.5%. STX3451, STX2895,
PF, or Frax1036 was replenished after 2 days of culture.
Cell growth was assessed using CellTiter 96 (Promega,
Madison, WI, USA) [30, 47, 48].
Fig. 1 Chemical structures of 2-MeE2, 2ME2BisMATE, STX2895 and STX3451
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Immunohistochemistry
40,000–80,000 cells plated on 0.1% porcine gel-coated
coverslips were treated with DMSO, STX3451,
STX2895, PF3758309, or Frax1036 for various time pe-
riods. Immunocytochemistry and counter-staining with
DAPI (4′,6-diamidino-2-phenylindole, Molecular Probes,
Eugene, OR), were carried out as reported previously
[45]. Microtubules were visualized using antibodies for
α-tubulin (1:500, Sigma). Apoptosis was assessed by an
anti-annexin V antibody (1:500, Abcam ab14196). Fluor-
escent (Alexa Fluor 488 or 594) anti-rabbit or anti-
mouse secondary antibodies (Life Technologies) were
used for visualizing the labeled cells. Fluorescence mi-
crographs were taken with an Olympus BX-51 micro-
scope and processed with Adobe Photoshop.
Wound-healing assays
The ability of cells to migrate was assessed by wound-
healing assays [49, 50]. 2 × 105 cells were plated in a 10
mm cell culture dish and allowed to grow to confluence.
Wounds were made using a ruler to maintain a straight
edge and a 200 μl pipette tip applied to the bottom of
the dish to remove the cells. The culture plates were
then washed twice with PBS. Fresh medium with
DMSO, STX3451, or STX2895 was added to the dishes.
STX3451 and STX2895 were used at 300 nM for KT21,
Ben-Men-1, and HEI-193 cells, 1000 nM for IOMM-Lee
and BJ cells. Photographs of the wounds and subsequent
cell migration and “wound filling” were taken using a
Nikon SMZ1500 dissecting microscope and digital cam-
era (Nikon Digital Sight) at the time points indicated.
The dimensions of the “wound” were measured with
ImageJ software.
Western blots
Cell lysates were collected after 24 h treatments with
DMSO, STX3451, STX2895, PF, or Frax1036. Western
blotting was performed as described in the studies on
NF1 [30]. Membranes were incubated with antibodies
(all from Cell Signaling Technology) to phosphorylated
S6, S6, cyclin D, phosphorylated MEK, MEK, Pak 1/2,
phospho-Pak1 (pPak1), phospho-Pak2 (pPak2) and
GAPDH. The peroxidase-coupled secondary antibody (1:
1000) and chemiluminescent HRP substrate (Millipore)
were used to detect the labeled bands. Pixel density was
quantified with ImageJ (NIH) software.
Results
The effects of nonsteroidal analogues of 2ME2BisMATE
on cell viability depend on NF2 status
The STX therapeutic agents tested are multifaceted in
their mechanisms of action. This study was directed at
discovering whether the mechanisms of action that make
the STX agents promising potential therapeutics for the
treatment of NF1 would also apply to the potential treat-
ment of NF2. Our previous studies concluded that the
agents’ effects on the growth of and induction of apop-
tosis in human NF1 tumour cells were both through
NF1-specific pathways and through significant effects on
both the actin-based and myosin-based cytoskeleton
[30]. The same approaches in the present study on NF2
led to the findings that, in NF2 human tumour cells,
none of the pathways that were found to be affected in
NF1 was affected in NF2. However, effects on NF2 cell
growth were also mediated through the STX agents’ ef-
fects on the cytoskeleton.
In our earlier report [30] we demonstrated that rela-
tively low concentrations of STX3451 have profound ef-
fects on the cell viability of NF1 tumour cell lines, even
in the presence of elevated oestrogen and progesterone
hormones. We also demonstrated that these effects were
caused by more than one mechanism of action. To
examine whether STX3451 or STX2895 affected the via-
bility of human NF2 tumour cells, in a manner similar
to those in NF1 tumour cells, we exposed Ben-Men-
1(NF2−/− benign meningioma cells), CH157MN (NF2−/−
meningioma cells), HEI-193 (NF2−/− benign vestibular
Schwannoma cells), KT21 (NF2−/− malignant meningi-
oma cells) and IOMM-Lee (NF2+/+ malignant meningi-
oma cells) to the individual agents or to a combination
of the two. Our results showed that both agents either
completely blocked cell proliferation or induced cell
death in NF2−/− cells whether the cell lines were derived
from benign or malignant tumours (Fig. 2). Cell prolifer-
ation of wild-type NF2 malignant meningioma IOMM-
Lee cells was notably reduced when treated with either
drug. In all but the CH157MN cell line, STX2895 was
slightly more potent than STX3451. BJ fibroblast cells
were seen to have reduced cell growth rate when treated
with either compound, but cell viability was not reduced
even with the highest concentrations of either drug we
used (1 μM).
Chow et al. had previously shown that Pak inhibitors
reduced proliferation and survival of both Ben-Men-1
and KT21 cells [41]. We set out to examine the effects
of such inhibitors on other NF2-null cells as well as
CH157MN cells. Our results demonstrate that Frax1036
(a group I Pak-specific inhibitor) is less potent than the
analogues of 2ME2BisMATE in promoting cell death of
either CH157MN or HEI-193 cells (Fig. 3). STX3451
halted CH157MN cell growth completely at a concentra-
tion of 1 μM, whilst STX2895 induced cell death at 300
nM. By contrast, these cell lines still grew relatively rap-
idly in 5 μM Frax1036. Only at 15 μM did Frax1036 in-
duce apoptotic cell death in CH157MN. PF3758309
(PF), an inhibitor for both groups I and II Paks, on the
other hand, was found to be more potent than STX3451
but less potent than STX2895 for CH157MN cells. PF at
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Fig. 2 Cell viability of NF2-null and NF2-wild type tumour cells in response to the 2ME non-steroidal sulfamate derivatives STX3451 and STX2895.
DMSO; STX3451 0.1 μM; STX3451 0.3 μM; STX3451 0.6 μM; STX3451 1 μM; STX2895 0.1 μM; STX2895 0.3 μM; STX2895 0.6 μM; STX2895 1 μM. Graphs
show the increase in absorbance (fold change) after 4 days of treatment compared to the levels at the beginning of the treatment
Fig. 3 Cell viability of NF2-null and NF2-wild type tumour cells after treatment with the Pak inhibitors PF3758309 and Frax1036. DMSO; PF
0.03 μM; PF 0.1 μM; PF 0.5 μM; PF 1 μM; PF 2.5 μM; PF 5 μM; PF 10 μM; PF 20 μM; Frax1036 2.5 μM; Frax1036 5 μM; Frax1036 7.5 μM; Frax1036
10 μM; Frax1036 15 μM; Frax1036 20 μM; Frax1036 25 μM
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500 nM halted cell growth of CH157 MN cells (Fig. 3),
whilst STX2895 and STX3451 had the same effect- halt-
ing CH157 MN cell growth- at 300 nM and 1000 nM, re-
spectively (Fig. 2). Both STX3451 and STX2895 were
very effective at low concentrations (100 nM) in promot-
ing the death of HEI-193. However, neither PF nor
Frax1036 proved to be as potent for reducing cell viabil-
ity in benign vestibular Schwannoma HEI-193 cells. We
did not test concentrations higher than 1 μM with the
non-steroidal analogues for any of the cell lines, except
for IOMM-Lee cells. PF3758309 began to cause cell
death in IOMM-Lee cells between 1 and 5 μM, whilst
the cells still grew – albeit at a lower rate – even at
7.5 μM Frax1036. BJ cells were less sensitive to PF and
Frax1036 than any of the tumour cell lines. Even at
20 μM, PF did not reduce BJ cell viability, although BJ
cell viability decreased at concentrations of Frax1036 be-
tween 5 and 10 μM. Of the 4 agents we tested, STX2895
was the most robust for inducing apoptosis in NF2
tumour cell lines. PF and STX3451 displayed about the
same potency, whilst Frax1036 was the least effective in
blocking cell proliferation or causing apoptosis.
Next we investigated the mode of action of STX
agents on the growth and/or induction of apoptosis in
NF2 tumour cells and compared the effectiveness of
these agents with those of Pak inhibitors. Our results,
which will be discussed in the next section, indicated
that STX agents caused depolymerization of microtu-
bules, whilst Pak inhibitors did not have this effect.
Despite carefully repeated experiments (n = 5 [at least],
on each of the cell lines) testing whether the STX agents
act mechanistically on the same pathways on which we
found them to be very effective on growth and apoptosis
in human NF1 tumour cell lines, we currently have been
able to detect NO significant effects of either of the
agents on the growth, morphology of NF2 cell lines
through the pathways that are known to be important
for the growth of or cell death in NF1 human tumour
cell lines (as detailed in Shen et al., 2015 [30]). This is an
important point, because if the STX agents successfully
reduce growth or induce apoptosis in NF2 cell lines as
they do in NF1 cell lines, understanding the mechanism
or mechanisms by which such effects occur is critical in
order to plan the required preclinical animal studies that
must follow the cell line studies if the agents are to be
helpful eventually to both NF1 and NF2 patients.
STX3451 and STX2895 cause nuclear fragmentation in
NF2-null tumour cells
Our previous studies on NF1 cell lines demonstrated
that STX3451 caused nuclear fragmentation in both the
NF1-null malignant tumour cell line ST88 and in benign
plexiform neurofibroma (PNF) cells, although this result
was less significant for PNF cells [30].
We therefore examined whether this effect was also
observed in our studies of NF2-null tumour cells. DAPI
staining revealed that treatment with both STX3451 and
STX2895 resulted in a dramatic increase in nuclear frag-
mentation, which was seen in both KT21 and Ben-Men-
1 cell lines 48 h after treatment; with STX3451being
more effective than STX2895 (Fig. 4). At 24 h, although
STX3451 increased nuclear fragmentation in KT21 cells,
the effect of STX2895 at this earlier time point was not
significant, implying that most of the fragmentation
caused by STX2895 occurred between 24 and 48 h after
treatment. Further, nuclei fragmentation of KT21 was
observed 72 h after treatment, with STX2895 more ef-
fective than STX3451, suggesting that STX2895 has a
slower but consistent pace in causing fragmentation of
nuclei.
For Ben-Men-1 cells, the dramatic increase seen in nu-
clei fragmentation also fell between 24 and 48 h after
treatment, with STX3451 slightly more effective than
STX2895. Neither analog caused significant increase of
fragmentation between 48 and 72 h, presumably due to
the greatly reduced cell viability seen during this time
Fig. 4 STX3451 and STX2895 caused nuclear fragmentation in both KT21 and Ben-Men-1 cells. DMSO control; STX3451; STX2895. Statistical
significance: *p < 0.05; **p < 0.01; ***p < 0.005
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(Fig. 2). However, the nonsteroidal sulfamate derivatives
of 2ME2 effectively promoted nuclear fragmentation in
both NF1 [30] and NF2 null tumour cell lines.
STX3451 and STX2895, but not the Pak inhibitors, induce
microtubular disruption; treatment with all agents
resulted in tumour cell apoptosis
STX3451 induced apoptosis and disrupted both micro-
tubule- and microfilament-based cytoskeletal structures in
NF1 ST88 cells, but did not induce programmed cell
death in the benign PNF tumour cells [30]. To analyze
apoptosis, we used an Annexin V antibody [51] to stain
cells treated with STX agents and PAK inhibitors for 72 h.
In healthy, quiescent cells phosphatidylserine (PS) is lo-
cated exclusively at the inner cell membrane. Exposure of
PS in a cell indicates early apoptosis [52]. Annexin V has a
high binding affinity for PS in the presence of Ca2+ and is
therefore commonly used to detect apoptotic cells.
For KT21 cells, treatment with both STX3451 and
STX2895 at 300 nM resulted in about 60% annexin V-
positive-cells (Fig. 5). Even at much higher concentra-
tions (7.5 μM and 2 μM, respectively), PF and Frax1036
resulted in only 30 and 20% of apoptotic KT21 cells at
72 h. Less than 10% of cells treated with the DMSO ve-
hicle were annexin V-positive. Except for Frax1036, the
increases seen in annexin V-positive cells are statistically
significant.
For Ben-Men-1 cells, although cell viability was little
affected after 4 days of treatment, about 40% of these
cells treated with either STX3451 or STX2895 (at 600
nM) were apoptotic at 72 h, indicating that these ana-
logues of 2ME2 also have effects on cell growth/apop-
tosis in the benign Ben-Men-1 cells. However, the
effects seen are much less than those seen when either
STX agent was used to treat malignant KT21 cells. By
contrast, 72 h treatment with PF resulted in 20% annexin
V-positive cells at very low concentration, the IC50 for
KT21 was 29.25 nM [41]. Frax1036 at 1.9 μM caused
30% of Ben-Men-1 cells to become apoptotic at 72 h.
Even though IOMM-Lee cell line viability was higher
after 4 days, despite treatment with STX3451 or
STX2895 at 1000 nM, annexin V-staining at 72 h dem-
onstrated that 35 and 45% of these cells were undergo-
ing cell death, respectively. The reason for this
inconsistency is not clear. It could be that cells were still
proliferating at earlier times, but eventually would be
killed by higher concentrations of these 2ME2 analogs.
Further studies are needed to determine the mechanism
of action of these agents in IOMM-Lee cells. PF at
1.5 μM and Frax1036 at 10 μM resulted in apoptosis in
about 25% of cells at 72 h, indicating that these agents
are less effective in killing IOMM-Lee cells than either
STX3451 or STX2895.
Finally, STX3451 and STX2895 at 1000 nM did not
significantly increase the percentage of annexin V-
positive BJ cells at 72 h, consistent with the results seen
in the cell viability assays (discussed above). At concen-
trations that effectively induced apoptosis in NF2
tumour cells, STX3451 and STX2895 did not cause such
programmed cell death in BJ fibroblasts. PF at 5 μM also
did not increase the percentage of annexin V-positive BJ
cells, whilst Frax1036 at 10 μM induced 55% cells to go
through apoptosis.
STX3451 has been demonstrated to depolymerize mi-
crotubules in both NF1 ST88 and PNF cell lines [30].
Our current studies also confirmed the effect of
STX3451 and STX2895 on microtubules in NF2-null
tumour cells. Both agents caused cells to round up and
to present with much shorter microtubules in all of the
cell lines examined (Fig. 5a). Failure of cytokinesis was
also seen in these treated cells, where cells with larger
diameters were observed (Fig. 5a). PF and Frax1036, in
contrast to the STX agents, did not result in microtubule
disruption in most of the cell lines tested. A high con-
centration of Frax1036 (10 μM) resulted in rosette-like
clusters of IOMM-Lee cells. However, the mechanism
for this rosette formation is unknown.
Our results from annexin V and α-tubulin staining
(Fig. 5) suggest that the two analogs of 2ME2 that
we evaluated act differently from the Pak inhibitors on
NF2 cells, especially in the effects seen on the microtu-
bular cytoskeleton. However, both STX agents and Pak
inhibitors can promote apoptosis in NF2 tumour cells.
STX3451 and STX2895 decrease cell migration
PF and Frax1036 have been shown to inhibit invasive-
ness of both KT21 and Ben-Men-1 cells [41]. We, there-
fore, explored the possibility that STX3451 and/or
STX2895 could also block cell migration in NF2-null
tumour cells using “wound-healing” assays [49, 50] as
we had previously done for NF1 cells [30]. We found
that the cell lines, which we evaluated migrated to fill
the wound gaps at different rates, and that STX3451 and
STX2895 inhibited wound healing in the NF2 cells with
different kinetics. The untreated control Ben-Men-1
cells were able to fill in the gaps by 4 days after the
wound was made. However, cells treated with either
STX3451 or STX2895 also filled in the gap, but at a
much slower pace (Fig. 6). Control KT21 cells did not
completely fill the gap even 4 days after the lesion was
made, although the gap was almost eliminated by this
time (Fig. 6a). KT21 cells treated with either STX3451
or STX2895 migrated to fill the gap at a much slower
rate than the control cells and stopped migration en-
tirely after 46 h. Both IOMM-Lee and HEI-193 cells
closed the gap in DMSO-treated cultures (the control
condition) after 4 days. However, STX3451 and
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STX2895 only slowed down the migration of these cells
slightly for the first 2 days. The distance cells migrated to
fill the gap by the third and fourth days was almost the
same as that seen in the control cells treated with the
DMSO vehicle, indicating that STX3451 and STX2895 did
not inhibit cell migration over a period of 4 days, if this
Fig. 5 a STX3451 and STX2895 resulted in cytoskeletal structural changes and apoptotic cell death in NF2 tumor cells after 72 h of treatment.
Cells were stained with DAPI for nuclei (blue), anti-α-tubulin antibody for microtubules (red), and annexin V for apoptotic cells (green). b Percentage of
annexin-V-positive cells for control and treated conditions. DMSO; STX3451; STX2895; PF; Frax1036. Statistical significance: *p < 0.05; **p < 0.01
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much time was allowed for recovery. Control BJ cells
healed the wound gradually over the 96 h period, whilst
cells treated with STX3451 and STX2895 migrated more
slowly, and the gap was not filled in until 4 days after injury.
Our results suggest that STX3451 and STX2895 are both
effective in impeding the migration of KT21, Ben-Men-1,
and BJ cells, but were less effective in preventing either
IOMM-Lee or HEI-193 cells from migrating.
Discussion
We previously demonstrated that STX3451 induces apop-
tosis in human NF1-deficient ST88 and S462 malignant
peripheral nerve sheath tumour (MPNST) cell lines at
very low concentration (300 nM), whilst arresting cell pro-
liferation in an NF1−/−benign plexiform neurofibroma
(PNF) [30]. In this study, using approaches and analyses
identical to those we previously used in our NF1 tumour
cell studies [30], we found that STX3451 and another po-
tent sulfamoylated non-steroidal compound, STX2895, ef-
fectively induced cell death in NF2 deficient cell lines
in vitro at concentrations between 0.3 μM and 1 μM.
These two compounds have similar potencies in most of
the NF2 cell lines, although STX2895 is slightly more po-
tent than STX3451.
Fig. 6 STX3451 and STX2895 treatment resulted in reduced cell migration of NF2 tumour cells and BJ cells after “wounding”. a Microscopic
pictures of wound healing assays showing introduction of the wound (0 h) and at the end of the observation period (96–118 h after wound
introduction). b Graphs show comparisons of the distances the cells moved from the wound periphery toward the middle of the open area at
various time points. DMSO; STX3451; STX2895
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Intriguingly, our results showed that STX3451 and
STX2895 were not as effective against a permanent NF2
wild type malignant meningioma cell line, IOMM-Lee,
indicating that NF2 status could be important for the ef-
fects of these compounds. Our results also showed that
these 2ME2 analogs were more potent than Pak inhibi-
tors in inducing cell death. However, their mechanistic
effects on the cells were different: STX3451 and
STX2895 affect microtubules (Fig. 5), whilst Pak inhibi-
tors act through the mTORC pathway and affect cell
cycle progression by reducing β-catenin signaling,
followed by reducing cyclin D1 expression [39]. Further,
Pak inhibitors did not affect microtubule polymerization
at the concentrations we used. Therefore, the 2ME2 ana-
logs provide a new means of treating NF2-related disor-
ders, and could potentially be combined with Pak
inhibitors in multi-drug approach treatments.
We also found that STX3451 and STX2895 caused nu-
clear fragmentation and apoptosis in NF2 deficient cells,
as shown by annexin V staining. We found that by 72 h
after treatment with STX3451, the percentage of annexin
V positive cells amongst the attached cells was 19 times
greater in KT21 and 4 times greater in Ben-Men-1 cells
than in control cells. Treatment with STX2895 resulted
in 20 times more annexin V positive KT21 cells and 4.5
times more Ben-Men-1 cells than that of the controls.
STX3451 and STX2895 also increased the percentage of
annexin V positive IOMM-Lee cells, but this increase
was not statistically significant, indicating that NF2 wild-
type tumour cells are less sensitive to the 2ME2 analogs.
In addition, as was also shown in our studies of NF1-
deficient cells [30], STX3451 caused microtubule
depolymerization in NF2-deficient cells. STX2895 had
very similar effects to those of STX3451 in NF2-
deficient cells. These effects on the cytoskeleton un-
doubtedly contribute to the decrease in cell migration
(Fig. 6) after treatment with the 2ME2 analogs, since dis-
rupting microtubules can affect cellular locomotion [53].
Both STX3451 [31] and STX2895 [32] have been shown
to inhibit tubulin assembly in vitro, presumably by bind-
ing to the colchicine-binding site of tubulin. Indeed, our
recent X-ray crystalographic study [54] has demon-
strated, in atomic detail, that a non-steroidal quinazoli-
none sulfamate derivative, similar to those investigated
here, can interact with the colchicine binding site and
microtubule destabilization is likely achieved by prevent-
ing the curved-to-straight conformational transition in α/
β-tubulin. This is the first atomic level demonstration of
such an interaction for a sulfamate ester. Associated crys-
tallographic work has also demonstrated the effectiveness
of STX3451 in binding to the colchicine site [55].
Our previous study showed that the non-steroidal analog
of 2ME2, STX3451, caused microtubule depolymerization
and cell death in NF1 deficient tumour cells, even in the
presence of elevated hormones [30]. Whether steroid hor-
mones affect the growth of NF2−/− vestibular schwannomas
(VS) and/or meningiomas has not been well-studied. It has
been shown that in sporadic VS, both oestrogen receptor
(ER) and progesterone receptor (PR) were up-regulated,
whilst in NF2-related VS, PR was down-regulated [56].
Amongst meningioma patients, two-thirds express PR (al-
though − 30% express PR at low levels), and during malig-
nant progression, PR expression tends to decrease [57]. PR-
negative meningiomas also tend to be larger than those that
are PR-positive [58], and expression of PR in meningiomas
is correlated with a favourable prognosis [59]. However,
several studies have shown that hormone replacement ther-
apy in postmenopausal women is associated with increasing
the risk of meningiomas [60, 61] and one case report
showed that cessation of long-term use of the PR agonist
megestrol acetate resulted in shrinkage of multiple men-
ingiomas in one patient [62]. Treatment of progressive
meningiomas with the PR antagonist mifepristone has not
shown promising results [63]. Therefore, hormone therap-
ies are not indicated and may even be contraindicated for
NF2-related tumours. The ability of STX3451 and
STX2895 to inhibit colchicine binding to microtubules
could play a major role in microtubule depolymerization
and subsequent death of NF2 cells. However, the fact that,
even at high concentration as 1 μM, BJ and IOMM-Lee
cells still proliferate, although at a slower pace than the
controls (Fig. 2), indicates that these small molecules could
interact with players in the Merlin pathway in addition to
their effects on microtubules. These possibilities need to be
further investigated.
Since Merlin affects several key signalling pathways in the
cytoplasm and nucleus, including PI3K signaling,
mTORC1, the RAS and Src pathways, the Hippo kinase
cascade, and CRL4-DCAF [64], inhibitors of these pathways
might serve as excellent candidates for drug targets. Indeed,
of the targeted drugs tested in clinics, bevacizumab, which
is a VEGF antibody, showed some improvement in hearing
and tumour shrinkage in a quarter to a half of patients with
VS, albeit in very small numbers of study subjects [23–25].
Some phase II clinical trials with bevacizumab are still on-
going. The results of treatments with everolimus, an mTOR
inhibitor, showed that it stabilized tumours or delayed
tumour growth [26], but was ineffective for progressive VS
[65]. Lapatinib, a tyrosine kinase inhibitor for the epithelial
growth factor receptor (EGFR), showed some success in re-
ducing VS volumes and improving hearing responses in
about one-quarter of a small group of patients in a phase II
study [22], but no effect on meningiomas. Other phase II
studies of this drug are also ongoing.
So far, none of the drugs tested in vitro or in pre-
clinical or clinical trials has been effective on NF2 men-
ingioma. Although, another mTOR inhibitor, AZD-2014,
and a combination of smoothened receptor inhibitor,
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vismodegib, and FAK inhibitor, vistusertib, are in phase
II trials. AR-42, a histone deacetylase inhibitor targeting
CRL4-DCAF, which induced meningioma cell apoptosis
in vitro and in xenografts, is also in phase I trials. Even
if some inhibitors for NF2/Merlin signalling pathways
have promising efficacy, drug resistance to these inhibi-
tors may eventually occur and alternative choices are ne-
cessary. The microtubule-disrupting non-steroidal 2ME2
analogs could provide another option for treating NF2-
related tumours, both vestibular Schwannomas and
meningiomas, either alone, or in conjunction with other
agents. Pre-clinical studies using several similar THIQ-
based molecules have been shown to be safe and effica-
cious for reducing the size of human breast cancer [66]
and melanoma xenografts [32, 45] in immunocomprom-
ised mice. Before testing the usefulness of STX3451 and
STX2895 in human schwannoma and meningioma pa-
tients, pre-clinical studies are warranted. It is our hope
that someday these small molecules can advance to
therapeutic use in such patients.
Conclusion
Both STX3451 and STX2895 provide new approaches
for inducing cell death and lowering tumour burden in
NF2 as well as in NF1, which both have limited treat-
ment options.
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